加载中
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
前收盘价
US$6.97
−US$0.13 · -1.83%
盘中时间采用ET。市场数据可能有所延迟。
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
日内区间
当前US$6.97
52周区间
当前US$6.97
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
33
偏贵
情绪
50
多空交织
风险
50
风险偏高
动量
61
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
日内区间
当前US$6.97
52周区间
当前US$6.97
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 8198.3万 USD | 8004.6万 USD | 8321.5万 USD | 7125.5万 USD | 6111.5万 USD |
| 销售、一般及管理费用 | 2124.5万 USD | 1800.6万 USD | 1600.8万 USD | 1526.3万 USD | 1330万 USD |
| 营业费用 | 1.03亿 USD | 9805.2万 USD | 9922.3万 USD | 1.19亿 USD | 9166.5万 USD |
| 利息收入 | 104万 USD | 339万 USD | 307.5万 USD | 104.1万 USD | 6.6万 USD |
| 利息支出 | — | — | — | 104.1万 USD | — |
| 折旧和摊销 | 16.8万 USD | 13.4万 USD | 11.1万 USD | 7.7万 USD | 8.5万 USD |
| 营业利润 | −1.03亿 USD | −9805.2万 USD | −9922.3万 USD | −1.19亿 USD | −9166.5万 USD |
| 净利润 | −9717.2万 USD | −1.01亿 USD | −9361.2万 USD | −1.2亿 USD | −9294.5万 USD |
公司数据更新于 2026年10月17日。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI371.15万0.00%2.3万亿 USD0.03%US$374.07-1.15%
Vanguard Extended Market ETFVXF148.1万0.00%912亿 USD0.05%US$226.57-1.80%
iShares Micro-Cap ETFIWC30.65万0.02%12.8亿 USD0.60%US$173.28-2.53%
Simplify Propel Opportunities ETFSURI21.42万0.30%7239.93万 USD2.82%US$17.06620.00%
Avantis U.S. Small Cap Equity ETFAVSC12.44万—30.74亿 USD0.25%US$69.30-0.86%
ALPS Medical Breakthroughs ETFSBIO11.72万0.07%1.73亿 USD0.50%US$50.12-4.02%
Invesco NASDAQ Future Gen 200 ETFQQQS5.36万0.25%2125.18万 USD0.20%US$38.3927-4.16%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCSimplify Propel Opportunities ETFSURIAvantis U.S. Small Cap Equity ETFAVSCALPS Medical Breakthroughs ETFSBIOInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
